Augusto Faria Andrade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Augusto Faria Andrade has a total of 303 co-authors. Here are the top co-authors by number of shared publications:
- Nada Jabado
Department of Human Genetics, McGill University, Montreal, Canada
83 shared publications - Claudia L. Kleinman
Lady Davis Research Institute, Jewish General Hospital, Montréal, Canada
78 shared publications - Manav Pathania
Department of Oncology and The Milner Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK
78 shared publications - Antonella De Cola
Department of Oncology, University of Cambridge , Cambridge
77 shared publications - Steven Hébert
Lady Davis Research Institute, Jewish General Hospital, Montréal, Canada
77 shared publications - Damien Faury
Department of Human Genetics, McGill University Health Center Research Institute
76 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
CD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- 10 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Open AccessCD155 regulates tumor growth and susceptibility to T cell-mediated killing in diffuse midline glioma
Background: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune-checkpoint inhibitors have failed to prolong survival of DMG patients. Methods: In this study, we screened for immune-checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by coculture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton (Thio). Results: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were cocultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 induced apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified Forkhead box M1 (FoxM1) as a key target of CD155. Notably, FoxM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thio, a FoxM1-targeting agent, delayed tumor growth and prolonged survival. Conclusions: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease.
- 18 May 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (6) , 1368-1382
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs
Polycomb repressive complex 2 (PRC2)-mediated histone H3 K27 trimethylation (H3K27me3) recruits canonical PRC1 (cPRC1) to maintain heterochromatin. In early development, Polycomb-regulated genes can display long-range three-dimensional interactions, many of which resolve during lineage differentiation. Here we report that Polycomb-anchored looping is controlled by H3K27me3 spreading and regulates target gene silencing to influence cell fate specification. Using glioma-derived H3 Lys27-to-Met (H3K27M) mutations as tools to restrict H3K27me3 spreading, we show that H3K27me3 confinement concentrates the chromatin pool of cPRC1, resulting in heightened three-dimensional interactions that mirror the chromatin architecture of pluripotency. Conversely, H3K27me3 spread in pluripotent stem cells dilutes local cPRC1 chromatin concentration, weakening Polycomb loop contact frequencies. Disruption of cPRC1 binding or aggregation compromises stringent repression of Polycomb genes and induces differentiation and tumor regression of H3K27M-mutant glioma. These results identify the regulatory principles and disease implications of Polycomb looping and show that histone-modification-guided distribution of reader complexes is an important mechanism for nuclear compartment organization.
- 18 May 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (6) , 1368-1382
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs
Polycomb repressive complex 2 (PRC2)-mediated histone H3 K27 trimethylation (H3K27me3) recruits canonical PRC1 (cPRC1) to maintain heterochromatin. In early development, Polycomb-regulated genes can display long-range three-dimensional interactions, many of which resolve during lineage differentiation. Here we report that Polycomb-anchored looping is controlled by H3K27me3 spreading and regulates target gene silencing to influence cell fate specification. Using glioma-derived H3 Lys27-to-Met (H3K27M) mutations as tools to restrict H3K27me3 spreading, we show that H3K27me3 confinement concentrates the chromatin pool of cPRC1, resulting in heightened three-dimensional interactions that mirror the chromatin architecture of pluripotency. Conversely, H3K27me3 spread in pluripotent stem cells dilutes local cPRC1 chromatin concentration, weakening Polycomb loop contact frequencies. Disruption of cPRC1 binding or aggregation compromises stringent repression of Polycomb genes and induces differentiation and tumor regression of H3K27M-mutant glioma. These results identify the regulatory principles and disease implications of Polycomb looping and show that histone-modification-guided distribution of reader complexes is an important mechanism for nuclear compartment organization.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-3, 7-9 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Tables describing statistical analyses, median survivals, IC50 values calculated from cell viability assays, primer sequences and antibodies.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3, 7-9 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Tables describing statistical analyses, median survivals, IC50 values calculated from cell viability assays, primer sequences and antibodies.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-27 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Figures describing hindbrain vs ganglionic eminence targeting strategies, each of the 16 models generated and validation that they expressed the introduced mutations, survival of GE vs CTX-electroporated embryos, and cell viability data shown in bar graph format.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-27 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Figures describing hindbrain vs ganglionic eminence targeting strategies, each of the 16 models generated and validation that they expressed the introduced mutations, survival of GE vs CTX-electroporated embryos, and cell viability data shown in bar graph format.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
SsGEA signatures derived from snRNA-seq data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
SsGEA signatures derived from snRNA-seq data.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Cell type ontologies derived from snRNA-seq data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Cell type ontologies derived from snRNA-seq data.
- Open Access
- 13 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdaf241
Preclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergy
BackgroundDespite intensive therapies, outcomes for high-risk pediatric brain tumors (PBTs) remain dismal, prompting the search for novel treatments. DNA methyltransferase inhibitors (DNMTi) have been shown to prime tumors to improve response to checkpoint inhibition. The aim of this study was to investigate the potential of decitabine (DAC), in combination with a PD-1 inhibitor, to improve survival in pediatric high-risk brain tumor models. Methods: Analysis of human PBT datasets was performed to determine gene expression levels of immune cell markers. Tumor response to DAC, with or without a PD-1 inhibitor, was tested in murine models representing H3-wildtype diffuse intrinsic pontine glioma (DIPG), H3K27-mutant diffuse midline glioma (DMG), atypical teratoid rhabdoid tumor (ATRT), and medulloblastoma (MB). CyTOF analysis of allograft tumors was performed to characterize changes within the tumor microenvironment. Results: Analysis of PBT subtypes revealed heterogeneous expression of immune cell markers, checkpoint receptors, and MHC molecules. DAC treatment decreased DNA methylation and increased neoantigen expression in human and mouse tumor cells. DAC treatment resulted in prolonged survival in syngeneic mouse models of DIPG and ATRT but not DMG and MB models. However, no added survival benefit was observed when combined with a PD-1 inhibitor. CyTOF analysis of mouse tumors revealed changes in local immune cell infiltration. Conclusions: DAC alone or in combination with a checkpoint inhibitor can alter the immune microenvironment in mouse tumor models. Changes were observed in H3-wildtype DIPG and ATRT models, suggesting that certain tumor subtypes may respond to immune priming with DNMTi.
- 13 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdaf241
Open AccessPreclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergy
BackgroundDespite intensive therapies, outcomes for high-risk pediatric brain tumors (PBTs) remain dismal, prompting the search for novel treatments. DNA methyltransferase inhibitors (DNMTi) have been shown to prime tumors to improve response to checkpoint inhibition. The aim of this study was to investigate the potential of decitabine (DAC), in combination with a PD-1 inhibitor, to improve survival in pediatric high-risk brain tumor models. Methods: Analysis of human PBT datasets was performed to determine gene expression levels of immune cell markers. Tumor response to DAC, with or without a PD-1 inhibitor, was tested in murine models representing H3-wildtype diffuse intrinsic pontine glioma (DIPG), H3K27-mutant diffuse midline glioma (DMG), atypical teratoid rhabdoid tumor (ATRT), and medulloblastoma (MB). CyTOF analysis of allograft tumors was performed to characterize changes within the tumor microenvironment. Results: Analysis of PBT subtypes revealed heterogeneous expression of immune cell markers, checkpoint receptors, and MHC molecules. DAC treatment decreased DNA methylation and increased neoantigen expression in human and mouse tumor cells. DAC treatment resulted in prolonged survival in syngeneic mouse models of DIPG and ATRT but not DMG and MB models. However, no added survival benefit was observed when combined with a PD-1 inhibitor. CyTOF analysis of mouse tumors revealed changes in local immune cell infiltration. Conclusions: DAC alone or in combination with a checkpoint inhibitor can alter the immune microenvironment in mouse tumor models. Changes were observed in H3-wildtype DIPG and ATRT models, suggesting that certain tumor subtypes may respond to immune priming with DNMTi.
- 15 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (10) , 1794-1806
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma
Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells—including resident microglia and bone marrow-derived macrophages—as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid–myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors.
- 15 September 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (10) , 1794-1806
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma
Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells—including resident microglia and bone marrow-derived macrophages—as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid–myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.